Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan;12(1):41-9.
doi: 10.1586/era.11.192.

Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer

Karim S El-Sahwi  1 , Peter E Schwartz, Alessandro D Santin
Affiliations
Review

Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer

Karim S El-Sahwi et al. Expert Rev Anticancer Ther. 2012 Jan.

Abstract

Endometrial cancer (EC) is the most common female genital malignancy in the USA. Most carcinomas arising from the uterus are estrogen dependent and are associated with obesity and hypertension. They are designated type I ECs and typically, due to their early diagnosis secondary to postmenopausal bleeding, have a good prognosis. By contrast, type II ECs develop in older patients, are not hormone dependent and are responsible for most recurrences and deaths from EC. Uterine serous cancer constitutes up to 10% of all endometrial tumors, and represents the most biologically aggressive variant of type II EC. This article will describe the most salient molecular markers that have been identified in uterine serous cancer, thus far with emphasis on the use of erbB2 (HER2/neu) as the first of a series of therapeutic markers for the treatment of this highly-aggressive subset of ECs.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. - PubMed
    1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17. - PubMed
    1. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22(1):21–29. Excellent review of uterine serous cancer (USC) with special emphasis on current treatment strategies based on the best evidence available. - PubMed
    1. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335(9):640–649. - PubMed
    1. Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol. 2006;18(5):494–499. Thorough review of the best published literature on USC in 2005. The manuscript thoroughly describes all aspects of diagnosis and management. - PubMed

Website

    1. Evaluation of Carboplatin/Paclitaxel with and Without Trastuzumab (Herceptin) in Uterine Serous Cancer. http://clinicaltrials.gov/ct2/results?term=NCT01367002.

Publication types

MeSH terms

Substances